FDA clears Heart Force's ballistocardiograph
This article was originally published in Clinica
Executive Summary
A digital ballistocardiograph (dBG) developed by Heart Force Medical has received 510(k) clearance from the US FDA. The dBG 300 device is a standalone, portable noninvasive cardiac performance monitor; it employs digital sensors to measure the recoil of the human body due to the momentum of the blood pumped by the heart. Vancouver, Canada-based Heart Force Medical intends the device to be used to monitor patients in critical care, as well as assessing cardiac performance other patients.